We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

155 hedge funds and large institutions have $631M invested in CRISPR Therapeutics in 2018 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 41 increasing their positions, 44 reducing their positions, and 52 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

7% less repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 44

1.64% less ownership

Funds ownership: 44.27% → 42.63% (-1.6%)

13% less funds holding

Funds holding: 179 → 155 (-24)

35% less call options, than puts

Call options by funds: $11.4M | Put options by funds: $17.5M

37% less capital invested

Capital invested by funds: $1.01B → $631M (-$377M)

42% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 52

Holders
155
Holders Change
-24
Holders Change %
-13.41%
% of All Funds
3.45%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
30
Increased
41
Reduced
44
Closed
52
Calls
$11.4M
Puts
$17.5M
Net Calls
-$6.11M
Net Calls Change
+$20.4M

Top Buyers

Rank Fund Capital Flow
1
OTPPB
Ontario Teachers' Pension Plan Board
Ontario, Canada
+$20.2M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$14.4M
3
FCM
Farallon Capital Management
California
+$8.04M
4
CS
Credit Suisse
Switzerland
+$6.22M
5
CCP
Clough Capital Partners
Massachusetts
+$6.2M

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$24M
2
O
OrbiMed
New York
-$22M
3
EC
EcoR1 Capital
California
-$10.1M
4
CC
Casdin Capital
New York
-$9.76M
5
JP Morgan Chase
JP Morgan Chase
New York
-$9.34M
Name Holding Trade Value Shares
Change 		Change in
Stake
FANJ
126
Financial Architects (New Jersey)
New Jersey
$9K +$10.4K +300 New
First Manhattan
127
First Manhattan
New York
$8K – – –
Daiwa Securities Group
128
Daiwa Securities Group
Japan
$7K – – –
GSC
129
G&S Capital
Colorado
$7K +$5.21K +150 +150%
FWM
130
Focused Wealth Management
New York
$6K – – –
GAM
131
Gemmer Asset Management
California
$6K – – –
WT
132
Whittier Trust
California
$6K – – –
EWM
133
Executive Wealth Management
Michigan
$6K +$7.47K +215 New
CCM
134
Cribstone Capital Management
Maine
$5K – – –
WAP
135
Wealthcare Advisory Partners
Pennsylvania
$4K – – –
PWM
136
PRW Wealth Management
Massachusetts
$4K +$4.35K +125 New
NFG
137
Next Financial Group
Texas
$4K +$4.52K +130 New
GWMIA
138
Global Wealth Management Investment Advisory
Florida
$4K +$5.21K +150 New
AA
139
AlphaMark Advisors
Kentucky
$3K – – –
Fifth Third Bancorp
140
Fifth Third Bancorp
Ohio
$3K – – –
US Bancorp
141
US Bancorp
Minnesota
$3K – – –
YWP
142
YorkBridge Wealth Partners
New York
$3K +$3.48K +100 New
WIM
143
Westside Investment Management
California
$2.86K – – –
MPWT
144
MassMutual Private Wealth & Trust
Connecticut
$2.14K +$2.61K +75 New
ASN
145
Advisory Services Network
Georgia
$2K – – –
LF
146
Lee Financial
Texas
$2K – – –
EWM
147
Elmwood Wealth Management
California
$2K +$2.23K +64 New
AWM
148
AllSquare Wealth Management
New York
$1K – – –
SBL
149
Sargent Bickham Lagudis
Colorado
$1K – – –
LC
150
Lindbrook Capital
California
$1K +$1.91K +55 New
4 5
6
7 8

CRSP Hedge Fund Activity: Q4 2018 in Review

155 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q4 2018, worth a combined $631M — down 37% from $1.01B a quarter earlier.

Sellers outnumbered buyers: 52 funds closed out of CRSP and 30 opened new positions — a net loss of 22 holders — while 44 trimmed existing stakes and 41 added.

The largest buyer was Ontario Teachers' Pension Plan Board, opening a new position worth an estimated $20.2M. The largest seller was Jennison Associates, exiting entirely with an estimated $24M sold.

  • 155 institutional investors held CRISPR Therapeutics (CRSP) as of Q4 2018, down from 179 in Q3 2018.
  • Funds reported $631M of CRISPR Therapeutics stock for Q4 2018, down 37% quarter-over-quarter.
  • 30 funds opened new CRISPR Therapeutics positions in Q4 2018 and 52 closed out, a net change of -22 holders.
  • The largest CRISPR Therapeutics buyer in Q4 2018 was Ontario Teachers' Pension Plan Board, an estimated $20.2M added.
  • The largest CRISPR Therapeutics seller in Q4 2018 was Jennison Associates, an estimated $24M sold.

Based on aggregated 13F filings for Q4 2018.